trending Market Intelligence /marketintelligence/en/news-insights/trending/jmti2vgfnghxeiyjt63pla2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

VBI Vaccines launches common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

VBI Vaccines launches common stock offering

VBI Vaccines Inc. started an underwritten public offering of its common shares.

The company plans to grant the underwriters a 30-day option to buy up to an additional 15% of the number of common shares offered in the public offering.

Net proceeds will be used to advance the company's research and development programs, including funding the pivotal phase 3 clinical program for Sci-B-Vac in the U.S., Europe and Canada; funding the phase 1/2a clinical study of VBI-1901 for glioblastoma; funding VBI-1501, VBI's cytomegalovirus vaccine candidate; and funding VBI-2601, the company's immuno-therapeutic candidate for hepatitis B.

Net proceeds will also be used for general corporate purposes, including working capital and capital expenditures.

BMO Capital Markets, Canaccord Genuity LLC and Oppenheimer & Co. Inc. are acting as joint book-runners for the offering.

VBI Vaccines is a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines.